vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs -0.7%, a 13.7% gap on every dollar of revenue. Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 0.6%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
AVNS vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $300.5M |
| Net Profit | $-1.3M | $39.0M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 13.0% |
| Revenue YoY | 0.7% | — |
| Net Profit YoY | 99.7% | -12.4% |
| EPS (diluted) | $-0.02 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $180.9M | $329.9M | ||
| Q3 25 | $177.8M | $330.2M | ||
| Q2 25 | $175.0M | $303.3M | ||
| Q1 25 | $167.5M | $318.5M | ||
| Q4 24 | $179.6M | $301.1M | ||
| Q3 24 | $170.4M | $305.5M | ||
| Q2 24 | $171.7M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | $-1.3M | $41.6M | ||
| Q3 25 | $-1.4M | $45.8M | ||
| Q2 25 | $-76.8M | $36.1M | ||
| Q1 25 | $6.6M | $42.1M | ||
| Q4 24 | $-397.3M | $35.5M | ||
| Q3 24 | $4.3M | $29.7M | ||
| Q2 24 | $1.8M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 16.1% | ||
| Q3 25 | 0.1% | 18.4% | ||
| Q2 25 | -42.6% | 16.3% | ||
| Q1 25 | 6.1% | 18.1% | ||
| Q4 24 | -233.0% | 14.7% | ||
| Q3 24 | 7.0% | 13.9% | ||
| Q2 24 | 3.7% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -0.7% | 12.6% | ||
| Q3 25 | -0.8% | 13.9% | ||
| Q2 25 | -43.9% | 11.9% | ||
| Q1 25 | 3.9% | 13.2% | ||
| Q4 24 | -221.2% | 11.8% | ||
| Q3 24 | 2.5% | 9.7% | ||
| Q2 24 | 1.0% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $-0.02 | $0.68 | ||
| Q3 25 | $-0.03 | $0.74 | ||
| Q2 25 | $-1.66 | $0.57 | ||
| Q1 25 | $0.14 | $0.65 | ||
| Q4 24 | $-8.64 | $0.55 | ||
| Q3 24 | $0.09 | $0.46 | ||
| Q2 24 | $0.04 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $990.8M |
| Stockholders' EquityBook value | $778.2M | $2.2B |
| Total Assets | $1.1B | $15.7B |
| Debt / EquityLower = less leverage | 0.12× | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $778.2M | $2.2B | ||
| Q3 25 | $778.0M | $2.2B | ||
| Q2 25 | $776.3M | $2.2B | ||
| Q1 25 | $839.4M | $2.2B | ||
| Q4 24 | $828.5M | $2.2B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $1.2B | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $1.1B | $15.8B | ||
| Q3 25 | $1.1B | $15.6B | ||
| Q2 25 | $1.0B | $15.4B | ||
| Q1 25 | $1.1B | $15.8B | ||
| Q4 24 | $1.2B | $16.3B | ||
| Q3 24 | $1.7B | $15.9B | ||
| Q2 24 | $1.7B | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $-38.7M | ||
| Q3 25 | $14.0M | $273.0M | ||
| Q2 25 | $6.8M | $-234.6M | ||
| Q1 25 | $25.7M | $5.8M | ||
| Q4 24 | $57.9M | $273.9M | ||
| Q3 24 | $23.0M | $515.6M | ||
| Q2 24 | $27.8M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $-55.5M | ||
| Q3 25 | $7.0M | $271.0M | ||
| Q2 25 | $-4.2M | $-234.6M | ||
| Q1 25 | $19.0M | $5.0M | ||
| Q4 24 | $53.1M | $266.8M | ||
| Q3 24 | $20.0M | $513.8M | ||
| Q2 24 | $21.9M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -16.8% | ||
| Q3 25 | 3.9% | 82.1% | ||
| Q2 25 | -2.4% | -77.4% | ||
| Q1 25 | 11.3% | 1.6% | ||
| Q4 24 | 29.6% | 88.6% | ||
| Q3 24 | 11.7% | 168.2% | ||
| Q2 24 | 12.8% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 5.1% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 6.3% | 0.0% | ||
| Q1 25 | 4.0% | 0.3% | ||
| Q4 24 | 2.7% | 2.4% | ||
| Q3 24 | 1.8% | 0.6% | ||
| Q2 24 | 3.4% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.93× | ||
| Q3 25 | — | 5.96× | ||
| Q2 25 | — | -6.50× | ||
| Q1 25 | 3.89× | 0.14× | ||
| Q4 24 | — | 7.71× | ||
| Q3 24 | 5.35× | 17.36× | ||
| Q2 24 | 15.44× | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
